Brief: Nls Pharmaceutics Announces 1-for-10 Reverse Share Split And Name Change In Connection With Proposed Merger With Kadimastem
29/10/2025 10:06
Oct 29 (Reuters) - NLS Pharmaceutics AG NLSP.O: NLS PHARMACEUTICS LTD. ANNOUNCES 1-FOR-10 REVERSE SHARE SPLIT AND NAME CHANGE IN CONNECTION WITH PROPOSED MERGER WITH KADIMASTEM NLS PHARMACEUTICS - REVERSE SPLIT EFFECTIVE IN SWITZERLAND ON OCTOBER 30, 2025 NLS PHARMACEUTICS - COMMON SHARES TO TRADE ON NASDAQ AS NCEL UNDER NEW NAME NEWCELX LTD Source text: ID:nPn5W1RwGa Further company coverage: NLSP.O
Recent news on NewcelX AG
See all newsBrief: Newcelx Announces Pricing Of $1.4 Million Equity Financing At 20% Premium Pricing
Brief: Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes
Brief: Newcelx Updates Corporate Presentation To Highlight Type 1 Diabetes Flagship Program
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing